LOGO
LOGO

Pfizer, QIAGEN's DxS Unit Reach Deal To Develop Companion Diagnostic Test Kit For PF-04948568 To Treat Glioblastoma Multiforme - Quick Facts

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Pfizer Inc. (PFE) Thursday said the company and DxS, a wholly owned subsidiary of QIAGEN N.V. (QGEN) reached an agreement to develop a companion diagnostic test kit for PF-04948568, an immunotherapy vaccine in development for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed. The EGFRvIII companion diagnostic would be developed and manufactured at QIAGEN's Center of Excellence for Companion Diagnostics in Manchester, UK.

Glioblastoma multiforme is the most common malignant primary brain tumor in adults and occurs in around 25,000 patients worldwide each year.

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.